메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Beyond Recovery: QUINEAR QN-071A Brings Professional Compression Therapy Home for Holiday Deals

NEW YORK, Oct. 25, 2025 -- When recovery becomes the new performance edge. True progress doesn't happen during exertion — it begins in recovery. For years, QUINEAR has led the evolution of professional-grade compression systems, making clinical technology accessible to everyday athletes. The QN-071A is the embodiment of that mission: a smart, science-driven leg recovery system designed to help your body rebuild stronger — right from home. Inside the Science Built on Professional Sequential Air Compression Technology, the QN-071A features four independent air chambers that
- 김갑성 기자
- 2025-10-25 00:07
Embracing the Gift of Life, Healing Little Hearts Together

[ 메디채널 김갑성 기자 ] Pantai Hospital Kuala Lumpur and Shangri-La Kuala Lumpur Unites Again to Support Children with Congenital Heart Disease for the Second Year KUALA LUMPUR, Malaysia, Oct. 24, 2025 -- In a powerful display of compassion, purpose, and partnership, Pantai Hospital Kuala Lumpur (PHKL) and Shangri-La Kuala Lumpur came together once more for their annual paediatric cardiac charity initiative, "Embracing the Gift of Life, Healing Little Hearts Together." This meaningful event marked the second year of collaboration between two institutions driven by a shared mission
- 김갑성 기자
- 2025-10-24 22:04
A Self-Reliant Future through HPV 9-Valent Vaccine Alliance: INNOVAX details Localization Strategy in Thailand at IPVS 2025

BANGKOK, Oct. 24, 2025 -- On October 23, 2025, Dr. Zhiming (Tiffany) Jiang, General Manager of Wantai Group, and Dr. Huirong (Harry) Pan, General Manager of Xiamen Innovax Biotech Co., Ltd. ("Innovax"), participated in the 37th International Papillomavirus Society (IPVS) Conference in Bangkok, Thailand. They chaired a dedicated symposium titled "A New Era of HPV Vaccines: The Efforts from Developing Country Manufacturers for Global Cervical Cancer Elimination," which sparked lively discussions among attending experts and scholars. Innovax's booth (#09) "Together Again
- 김갑성 기자
- 2025-10-24 20:20
Terumo Interventional Systems Announces Its New OPUSWAVE® Dual Sensor Imaging System and DualView® Imaging Catheter Receive FDA 510(k) Clearance

OPUSWAVE Imaging System combines OFDI and IVUS into a single catheter, providing significant potential to reduce procedural time and costs in treating coronary artery disease DualView imaging catheter offers a 150mm maximum pullback length, a 2.6 Fr. imaging profile, 6 Fr. guide compatibility and a variable pullback speed of up to 40mm/second in dual mode SOMERSET, N.J., Oct. 24, 2025 -- Terumo Interventional Systems (TIS), a division of Terumo Corporation, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its OPUSWAVE® Dual Sensor I
- 김갑성 기자
- 2025-10-24 20:00
The Future of Life Sciences, Omics and AI Examined by Leading Global Genomic Experts

[ 메디채널 김갑성 기자 ] Groundbreaking Human-Centric Genomic Foundation Model Unveiled HANGZHOU, China, Oct. 24, 2025 -- The future of Omics and AI in life sciences is the central theme for more than 100 scientists and guests from 19 countries and regions gathered in Hangzhou, China, for the 20th Annual Meeting of the International Conference on Genomics (ICG-20) this week. Discussions will span global collaboration in omics and AI, cancer genomics, biodiversity and multi-omics of deep-sea organisms, metagenomics and epidemiology, public health and precision medicine, and the transfor
- 김갑성 기자
- 2025-10-24 18:13
Ribo Granted EMA Orphan Drug Designation for siRNA Therapeutic RBD1016 for Hepatitis Delta Virus (HDV) Infection

BEIJING and GOTHENBURG, Sweden, Oct. 24, 2025 -- Suzhou Ribo Life Science Co., Ltd. and Ribocure Pharmaceuticals AB (Ribo), today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to RBD1016 for the treatment of Hepatitis D Virus (HDV) infection. The EMA's ODD is assigned to investigational therapies of life-threatening or chronically debilitating rare diseases that affect no more than five in 10,000 individuals in the European Union. The ODD status provides significant regulatory and commercial incentives, thus enabling
- 김갑성 기자
- 2025-10-24 18:12
AXA Garners Seven Awards at The Hong Kong Insurance Awards 2025

HONG KONG, Oct. 24, 2025 -- AXA Hong Kong and Macau ("AXA") received seven accolades at The Hong Kong Insurance Awards 2025, including three winners and four top 3. The awards spanned key areas such as strategic partnerships, product innovation, AI and analytics, digital transformation, ESG and sustainability, corporate social responsibility, and the demonstrated professionalism and industry expertise of our financial consultants. This recognition underscores AXA's continued leadership in innovation and customer-centric excellence across products and services. It also reflects the C
- 김갑성 기자
- 2025-10-24 17:55
Pfizer and BioNTech Receive Health Sciences Authority Approval for SARS-CoV-2 Sublineage LP.8.1-Adapted Monovalent COVID-19 Vaccine in Singapore

The updated COVID-19 vaccine is expected to be available in Singapore at selected polyclinics and private general practitioner (GP) clinics in October 2025 for individuals 6 months of age and older. SINGAPORE, Oct. 24, 2025 -- Pfizer Singapore and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Health Sciences Authority has approved the companies' LP.8.1-adapted monovalent COVID-19 vaccine (COMIRNATY® LP.8.1; COVID-19 Vaccine, mRNA) for use in individuals 6 months of age and older, according to official recommendations*. This marks Singapore a
- 김갑성 기자
- 2025-10-24 17:33
Global Launch Event for iza-bren Phase III Nasopharyngeal Carcinoma Research Results Successfully Held, Streamed on ESMO Official Website

SHANGHAI, Oct. 24, 2025 -- At 15:00 Beijing Time (09:00 am Berlin Time) on October 20, the "Global Launch Event for Iza-bren (EGFR×HER3 Bispecific ADC) Nasopharyngeal Carcinoma BL-B01D1-303 Research Results" was held at the venue of the 2025 European Society for Medical Oncology (ESMO) Congress in Berlin. eChinaHealth held a forum on progress of nasopharyngeal carcinoma, and Biokin Pharma participated in sharing the research results and reported the Iza bren BL-B01D1-303 research report. The Launch Event focused on the BL-B01D1-303 study (hereinafter: 303 Study) led by
- 김갑성 기자
- 2025-10-24 16:40
Gushengtang TCM and 1doc Form Strategic Partnership to Establish Singapore's Integrated TCM Service Model

SINGAPORE, Oct. 24, 2025 -- Gushengtang TCM officially launched its "Master TCM AI" system at GovWare 2025 on October 22. The launch coincides with a strategic partnership with 1doc and a signed agreement with August Global Partners (AGP) for strategic investment, supporting the shift toward evidence-based integrative medicine. Gushengtang's senior leadership, including Founder and Chairman Tu Zhiliang, Group Vice President Zheng Xiang and Vice President Vicky Liem, Chief Technology Officer Hu Zhongkai, and Southeast Asia Vice General Manager Shen Lin, were present at
- 김갑성 기자
- 2025-10-24 15:08

이전

71 72 73 74 75 76 77 78 79 80

많이 본 기사

최근기사

2026-01-01_THU

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 01월 01일 22시 40분